SLC4A1 (Band 3 / AE1 / CD233) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 30 Sep 2026
  • Comments

Market Intelligence for Malaria Invasion Inhibition, Erythrocyte Membrane Disorder Therapeutics, and Rare Renal Disease

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for SLC4A1 drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen (Mutants/Isoforms) SLC4A1 Mutants / Isoforms
Sequence Verified, Endotoxin Controlled.		 View SLC4A1 Products
Antigen (Loop-Fc Fusion) Band 3 Extracellular Loop-Fc Fusion (Loop 3/7/11)
High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed.		 View SLC4A1 Products
Complex Membrane SLC4A1 Full-Length Lentivirus Premade Particles
For stable cell line construction preserving native 14-TM topology.		 View SLC4A1 Products
Gene Delivery SLC4A1 Promise-ORF / Lentivirus
Full-length ORF for stable cell lines; wild-type and disease mutants (SAO, dRTA variants).		 View SLC4A1 Products
Benchmark Ab Anti-SLC4A1 Benchmark Antibody (Clone BRIC170/BRIC6)
Recombinant positive controls for assay normalization and epitope mapping.		 View SLC4A1 Products
Validator SLC4A1 siRNA Set
For knockdown verification and specificity checks in non-erythroid models.		 View SLC4A1 Products
Related Target: Glycophorin A (GPA) Critical co-receptor; forms native complex with Band 3 on erythrocyte membranes; synergistic malaria invasion pathway. View GPA Products
Related Target: MSP1 Plasmodium falciparum MSP1
Primary invasion ligand that binds SLC4A1 during malaria infection.		 View MSP1 Products
Related Target: SLC4A4 (NBCe1) Kidney-specific bicarbonate transporter for dRTA cross-selectivity screening. View SLC4A4 Products
Related Target: SLC4A3 (AE3) Cardiac/brain isoform for off-target safety profiling. View SLC4A3 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Complex 12-14 Transmembrane Domain Conformation Full-Length Lentivirus for Stable Cell Lines (HEK293 or K562). Preserves native glycosylation and topology.
Differentiating Erythroid (eAE1) vs. Kidney (kAE1) Isoforms Strictly sequence-verified ORF clones for precise isoform expression.
Extracellular Loop Accessibility Defined Loop-Fc Fusions (Loop 3, 7, 11) with Theoretical MW verified by Mass Spec.
Cross-species Malaria Modeling Human/Mouse/Cyno Band 3 ortholog proteins available with >95% purity.
Disease Variant Screening SAO (Lys56Glu/Val), dRTA mutants (R589H, G609R) as sequence verified proteins and ORF clones.
Control Validation & False Positive Mitigation Clinical Benchmark Antibodies included; validated siRNA for specificity checks.

Live SLC4A1 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for SLC4A1 (Band 3) therapeutics operates at the intersection of infectious disease, rare genetic disorders, and hematology. As the most abundant integral protein of the human erythrocyte membrane, it is a focal point for novel antimalarial strategies aiming to block Plasmodium falciparum invasion via receptors like PfRh4. Simultaneously, drug developers are targeting specific mutant variants of kidney-specific AE1 (kAE1) with chaperone-like small molecules to treat distal renal tubular acidosis (dRTA). In sickle cell disease (SCD), stabilizing Band 3 interaction with the membrane skeleton may improve red cell deformability. Gene therapy approaches for hereditary spherocytosis (HS) and Southeast Asian ovalocytosis (SAO) are also advancing. The next wave of R&D is shifting toward highly specific peptide inhibitors, allosteric small molecules, and gene modulation therapies that bypass traditional resistance.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Peptide Inhibitor TargeThera, NYU Langone Malaria Prophylaxis Loop 3/Loop 7 Binding SPR (Need high-purity ECD-Fc)
Small Molecule Academic / Orphan Pharma, Consortia dRTA, Hemolytic Anemia, Sickle Cell Disease Anion Transport Assay & RBC Membrane Stabilization (Need Lentivirus for Cell Lines)
Monoclonal Ab NIH Malaria Initiative Malaria Treatment Cross-reactivity with SLC4A4/AE3 (Need Isoform Panel)
Gene Therapy Intellia, Beam Therapeutics Hereditary Spherocytosis Mutant vs WT Protein Expression (Need dRTA/SAO mutants)